Citron Reports Further Results from Laboratory Testing:
Questcor is Deceiving the FDA and Investors
H.P. Acthar Gel’s Specified Active Ingredient Less Than 20% of the Label Specification
Bioactivity of Deamidated Hormone Fragment Far Lower than Pure ACTH
The FDA has been Notified
Citron reports on further lab data submitted to FDA, that the contents Questcor’s only revenue-generating drug product, H.P. Acthar Gel, does not match its label or the official product insert the label. Questcor spins one story for Wall Street, and another for the medical community, but the regulatory risk here cannot be overstated.
https://citronresearch.com/wp-content/uploads/2014/03/qc1.jpg600700Citron Research/wp-content/uploads/2017/05/CitronLogo2017-350x65-1.pngCitron Research2014-03-14 07:08:132018-05-04 17:27:22Questcor is Deceiving the FDA and Investors